Back to Search Start Over

Differential action of 3-hydroxyanthranilic acid on viability and activation of stimulated lymphocytes

Authors :
Alberto Tommasini
Giuliana Decorti
Eva Cuzzoni
Sara De Iudicibus
Elisa Piscianz
Erica Valencic
Piscianz, Elisa
Cuzzoni, Eva
DE IUDICIBUS, Sara
Valencic, E.
Decorti, Giuliana
Tommasini, A.
Source :
International Immunopharmacology. 11:2242-2245
Publication Year :
2011
Publisher :
Elsevier BV, 2011.

Abstract

article i nfo Lymphocytes proliferation after antigen-driven activation leads to an increase in cell count, which could last some week, until apoptosis mechanisms allow the homeostatic control of the system. During the first days of this stimulation, activated lymphocytes display high resistance to apoptosis and to most immunosuppressive drugs. According to the literature, few compounds have been described to kill recently activated cells, by inhibiting metabolic processes fundamental to proliferation. The aim of our work was to evaluate comparatively these different compounds, in order to identify the best strategy to kill cells that have undergone proliferation, while sparing the repertoire of resting cells. After preliminary experiments, 3-HAA and bortezomib were selected as the most suitable compounds for our purposes. The possible synergic effect of 3-HAA with bortezomib or with manganese ions was also assessed. 3-HAA was confirmed to be the most reliable pharmacologic approach to inhibit proliferation with acceptable toxicity on resting cells. While in the case of PHA stimulation 3-HAA led to death of most lymphocytes, only a minor percentage of cells were killed after allo-stimulation, suggesting that the effect is proportional to the percentage of stimulated lymphocytes. Manganese ions further enhanced this effect, while results with bor- tezomib seemed to be less consistent. These results deserve further investigations to develop new procedures for targeting activated cells with pharmacological approaches.

Details

ISSN :
15675769
Volume :
11
Database :
OpenAIRE
Journal :
International Immunopharmacology
Accession number :
edsair.doi.dedup.....85159e803e055e3e23730511e6b81977